F1305-12 Pern F, Bogdanova N, Schürmann P, Lin M, Ay A, Länger F , Hillemanns P, Christiansen H, Park-Simon TW, Dörk T: Mutation Analysis of BRCA1, BRCA2, PALB2 and BRD7 in a Hospital-Based Series of German [...] von Deimling A, Hartmann C ; German Glioma Network: 2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int J Cancer 2012; 131(3): [...] 841-52 Hille U, Soergel P, Länger F , Schippert C, Makowski L, Hillemanns P: Aromatase Inhibitors as Solely Treatment in Postmenopausal Breast Cancer Patients. Breast J 2012; 18(2): 145-50 Hueper K, Elalfy

Supplement 1, Band 2: S.105, Abstract P39. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoskopische vs. offene Appendektomie. Eine gesundheitsökonomische Analyse. Posterpräsentation am 2. nationalen [...] Deutschland. Abstract P15. GMS 2008. Doc08 ebmP15. ISBN: 978-3-938975-16-9 . Gorenoi V, Schönermark MP, Hagen A. Nutzen und Risiken hormonaler Kontrazeptiva bei Frauen. Posterpräsentation am 2. nationalen Pr [...] 24-27.10. 2007, Dresden, Deutschland. Prävention und Gesundheitsförderung 2007, Supplement 1, Band 2: S.106, Abstract P40. Gorenoi V, Dintsios CM, Schönermark MP, Hagen A. Laparoscopic vs. open Appendectomy

in Delta1 mutants. PNAS , 104, 537-542. Limbourg A., Ploom M., Elligsen D., Sörensen I., Ziegelhoeffer T., Gossler A., Drexler H. and Limbourg F. P. (2007) The Notch Ligand Delta-like 1 (Dll1) is Essential [...] A., 2018. The ectodomains determine ligand function in vivo and selectivity of DLL1 and DLL4 toward NOTCH1 and NOTCH2 in vitro. Elife 7, 25477. doi:10.7554/ eLife .40045 Beckers, A., Ott, T., Schuster-Gossler [...] intracellular domain of DLL1 argues against reverse signaling by DLL1 in vivo. PLoS ONE 8 , e79050. Zender, S., Nickeleit, I., Wuestefeld, T., Sörensen, I., Dauch, D., Bozko, P., El-Khatib, M., Geffers,

Rijal R, Frommolt P, Wagle P, Konertz R, Faix J, Meßling S, Eichinger L. Functional Characterization of Ubiquitin-Like Core Autophagy Protein ATG12 in Dictyostelium discoideum. Cells. 8(1). Marinović M, Mijanović [...] 1809-1823. Böttcher RT, Veelders M, Rombaut P, Faix J, Theodosiou M, Stradal TE, Rottner K, Zent R, Herzog F, Fässler R. Kindlin-2 recruits paxillin and Arp2/3 to promote membrane protrusions during initial [...] 216, 3785-3798. Dräger NM, Nachman E, Winterhoff M, Brühmann S, Shah P, Katsinelos T, Boulant S, Teleman AA, Faix J, Jahn TR. Bin1 directly remodels actin dynamics through its BAR domain EMBO Rep. 18,

factor in breast cancer patients. Breast Cancer Res Treat 2007; 102(1): 1-6 Göhring G, Karow A, Steinemann D, Wilkens L, Lichter P, Zeidler C, Niemeyer C, Welte K, Schlegelberger B: Chromosomal aberrations [...] J Comp Pathol 2007; 137(1): 1-8 Hussein K, Bock O, Ballmaier M, Göhring G, Steinemann D, Lehmann U, Kemper J, Buhr T, Kreipe H: Familial polycythemia vera with non-germ line JAK2V617F mutation sparing the [...] Heterogeneous p27(Kip1) expression within primary renal cell cancers, their invasive margins and peritumoral renal parenchyma correlation with pathological and prognostic features. Urol Int 2007; 79(2): 164-9

Krabisch P, Just M, Augustin D, Liedtke C, Chao C, Shak S, Wuerstlein R, Kreipe HH, and Harbeck N (2017). Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast [...] Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res . 32:214-223 Christgen M*, Bartels S, Kreipe H (2025). NMD-insensitive CDH1 mutation as a mechanism for [...] Prat A, Schmid P, Baehner R, Kreipe HH, Solomayer EF, and Harbeck N* (2025). HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB,

ssler, K., Petry M., Barnett, P., Christoffels, V.M., Kispert, A. (2013) Tbx2 Controls Lung Growth by Direct Repression of the Cell Cycle Inhibitor Genes Cdkn1a and Cdkn1b. PLoS Genet. 9, e1003189. Mommersteeg [...] Kruspe, D., Kispert, A., Hänel, F., and Christoph Englert, C. (2010). Sipl1 and Rbck1 are novel Eya1-binding proteins with a role 1 in craniofacial development. Mol. Cell. Biol. 30, 5764-5775. Airik, R., [...] 34(2):273-290. 2022010050. doi: 10.1681/ASN.2022010050. Deuper, L., Meuser, M., Thiesler, H., Jany, U.W.H., Rudat, C., Hildebrandt, H., Trowe, M.-O., Kispert, A. (2022). Mesenchymal FGFR1 and FGFR2 control

effects on the transport activity of anion exchanger AE1/SLC4A1. J Physiol 591: 4963-4982. 91. Aliuos, P., Fadeeva, E., Badar, M., Winkel, A., Mueller, P.P., Warnecke, A., et al (2013) Evaluation of single-cell [...] (2014) Rac1-dependent recruitment of PAK2 to G2 phase centrosomes and their roles in the regulation of mitotic entry. Cell Cycle 13: 2211-2221. 78. Menon, M.B., Sawada, A., Chaturvedi, A., Mishra, P., Sch [...] , Kapopara, P. R., Sedding, D. G., Gaestel, M., Bauersachs, J., and Bavendiek, U. (2016). Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice

Begemann G, Kienlin P, Hradetzky S , Niebuhr M, Eiz-Vesper B, Hennig C, Hansen G, Baron-Bodo V, Moingeon P, Werfel T: Der p1 and Der p2-Specific T Cells Display a Th2, Th17, and Th2/Th17 Phenotype in Atopic [...] skin-associated autoallergen α-NAC activates monocytes and dendritic cells via TLR-2 and primes an IL-12-dependent Th1 response. J Invest Dermatol. 2013 Sep;133 (9):2289-92. Hradetzky, S : Monocyte and [...] R, Werfel T: Zytokineffekte des Autoallergens α-NAC (Hom s 2): mögliche Bedeutung für die atopische Dermatitis. Allergo Journal. 2012; 21 (1): 38 [Abstract] (24. Mainzer Allergie-Workshop, 2012, Mainz

gen: 1.) Untersuchungen zur physiologischen Funktion der MAPK-aktivierten Proteinkinasen 2 und 2 (MK2/3) im Skellettmuskel und im Herzen von doppel-knockout-Mäusen sowie in der Muskelzelllinie C2C12; 2 [...] untersucht. Soweit bekannt, bewirkt ein Absinken von [Ca2+]i , sowie die Aktivierungen der p38 MAPK (Isoform a/b) und des Transkriptionsfaktors MEF2C, die Genexpression der schnellen fasertyp-spezifischen [...] konnten wir zeigen, dass NFATc1 durch weiter posttranslationale Modifikationen (PMTs) verändert wird. Weiterhin sind mitogen-aktivierte Proteinkinasen (MAPKs), insbesondere die p38 MAPK und möglicherweise